RAPP (Rapport Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 29, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-05-29), Rapport Therapeutics's share price is $9.51. Rapport Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.97. Hence, Rapport Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Rapport Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

RAPP's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.23
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Rapport Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.57. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.97.

Rapport Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Rapport Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Price-to-Operating-Cash-Flow Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Rapport Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Rapport Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapport Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Rapport Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Rapport Therapeutics Price-to-Operating-Cash-Flow Calculation

Rapport Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	9.51	/	-2.973
	=

Rapport Therapeutics's Share Price of today is $9.51.
Rapport Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.97.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Rapport Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.